KR100816267B1 - Cosmetic composition containing cheonsangcho extract as an active ingredient - Google Patents
Cosmetic composition containing cheonsangcho extract as an active ingredient Download PDFInfo
- Publication number
- KR100816267B1 KR100816267B1 KR1020070071439A KR20070071439A KR100816267B1 KR 100816267 B1 KR100816267 B1 KR 100816267B1 KR 1020070071439 A KR1020070071439 A KR 1020070071439A KR 20070071439 A KR20070071439 A KR 20070071439A KR 100816267 B1 KR100816267 B1 KR 100816267B1
- Authority
- KR
- South Korea
- Prior art keywords
- effect
- extract
- cheonsangcho
- cosmetic composition
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000284 extract Substances 0.000 title claims abstract description 83
- 239000002537 cosmetic Substances 0.000 title claims abstract description 55
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 239000004480 active ingredient Substances 0.000 title claims abstract description 9
- 230000000694 effects Effects 0.000 claims abstract description 43
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 20
- 230000002087 whitening effect Effects 0.000 claims abstract description 14
- 230000003020 moisturizing effect Effects 0.000 claims abstract description 11
- 206010040880 Skin irritation Diseases 0.000 claims abstract description 8
- 230000003712 anti-aging effect Effects 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000006071 cream Substances 0.000 claims description 13
- 238000009472 formulation Methods 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 5
- 239000006210 lotion Substances 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- 230000001153 anti-wrinkle effect Effects 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 241000248416 Rhododendron brachycarpum Species 0.000 claims description 2
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 2
- 238000002137 ultrasound extraction Methods 0.000 claims description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 2
- 229940058015 1,3-butylene glycol Drugs 0.000 claims 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims 1
- 235000019437 butane-1,3-diol Nutrition 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000000686 essence Substances 0.000 claims 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 238000000638 solvent extraction Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 12
- 210000002950 fibroblast Anatomy 0.000 abstract description 9
- 230000006872 improvement Effects 0.000 abstract description 9
- 230000037303 wrinkles Effects 0.000 abstract description 8
- 230000032683 aging Effects 0.000 abstract description 7
- 230000036556 skin irritation Effects 0.000 abstract description 5
- 231100000475 skin irritation Toxicity 0.000 abstract description 5
- 230000037380 skin damage Effects 0.000 abstract description 2
- 230000000638 stimulation Effects 0.000 abstract description 2
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 230000007794 irritation Effects 0.000 abstract 1
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 30
- 210000003491 skin Anatomy 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 21
- 238000002835 absorbance Methods 0.000 description 20
- 230000002401 inhibitory effect Effects 0.000 description 19
- 238000004519 manufacturing process Methods 0.000 description 17
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 15
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 230000005764 inhibitory process Effects 0.000 description 14
- -1 pack Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 10
- 239000012488 sample solution Substances 0.000 description 10
- 108010035532 Collagen Proteins 0.000 description 9
- 102000008186 Collagen Human genes 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 229920001436 collagen Polymers 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 230000008099 melanin synthesis Effects 0.000 description 9
- 150000003254 radicals Chemical class 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 8
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 8
- 230000037394 skin elasticity Effects 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 230000003013 cytotoxicity Effects 0.000 description 7
- 231100000135 cytotoxicity Toxicity 0.000 description 7
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 239000000344 soap Substances 0.000 description 7
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 7
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000007760 free radical scavenging Effects 0.000 description 6
- 210000002752 melanocyte Anatomy 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 4
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 4
- 102000003425 Tyrosinase Human genes 0.000 description 4
- 108060008724 Tyrosinase Proteins 0.000 description 4
- 229960000271 arbutin Drugs 0.000 description 4
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 4
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 239000012085 test solution Substances 0.000 description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102100033220 Xanthine oxidase Human genes 0.000 description 3
- 108010093894 Xanthine oxidase Proteins 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000019171 interleukin-1 alpha production Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000003061 melanogenesis Effects 0.000 description 3
- 210000002780 melanosome Anatomy 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 235000020944 retinol Nutrition 0.000 description 3
- 239000011607 retinol Substances 0.000 description 3
- 229960003471 retinol Drugs 0.000 description 3
- 230000002000 scavenging effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 229940075420 xanthine Drugs 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical group C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 108010050808 Procollagen Proteins 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000036570 collagen biosynthesis Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 2
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 2
- 229960004705 kojic acid Drugs 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- CKJGHPBOPQNPHM-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanol;sodium Chemical compound [Na].OCCN(CCO)CCO CKJGHPBOPQNPHM-UHFFFAOYSA-N 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 241001573881 Corolla Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 241000208422 Rhododendron Species 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000011539 homogenization buffer Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- AKPUJVVHYUHGKY-UHFFFAOYSA-N hydron;propan-2-ol;chloride Chemical compound Cl.CC(C)O AKPUJVVHYUHGKY-UHFFFAOYSA-N 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000005061 intracellular organelle Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- NEMFQSKAPLGFIP-UHFFFAOYSA-N magnesiosodium Chemical compound [Na].[Mg] NEMFQSKAPLGFIP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003101 melanogenic effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 항산화 효과, 피부노화 방지 효과, 피부주름 개선 효과, 미백 효과, 자외선에 의한 피부자극 완화 효과 및 보습 효과를 갖는 천상초 추출물을 유효성분으로 함유하는 화장료 조성물 및 상기 화장료 조성물을 인간의 피부에 도포하는 것을 특징으로 하는 화장방법에 관한 것이다. 본 발명에 의하면 천상초 추출물은 항산화능 뿐만 아니라 인간 섬유아세포활성효과, 피부 잔주름 개선효과, 미백효과, 자외선에 의한 피부손상 완화 효과 및 자극 완화 효과가 있어 이 물질을 이용하여 각종 기능성 화장료를 제조할 수 있다.The present invention is a cosmetic composition and the cosmetic composition containing the cheonsangcho extract having an antioxidant effect, skin anti-aging effect, skin wrinkle improvement effect, whitening effect, ultraviolet stimulation effect and moisturizing effect as an active ingredient and the cosmetic composition to human skin It relates to a makeup method characterized in that the coating. According to the present invention, the cheonsangcho extract has not only antioxidant activity but also human fibroblast activity effect, skin fine wrinkle improvement effect, whitening effect, skin damage relieving effect and irritation relieving effect, and various functional cosmetics can be prepared using this substance. have.
천상초, 노화, 주름, 미백, 피부자극, 보습 Cheonsangcho, aging, wrinkle, whitening, skin irritation, moisture
Description
본 발명은 천상초를 유효성분으로 함유하는 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition containing cheonsangcho as an active ingredient.
노화는 자외선, 스트레스, 질병상태, 환경인자, 상처, 나이가 들어감에 따라 프리라디칼이 활성화되어 야기될 수 있으며, 이런 상태가 심화될 경우 생체 내에 존재하는 항산화 방어망을 파괴하고, 세포 및 조직을 손상시켜 성인병 및 노화를 촉진하게 된다. 특히 단백질의 산화는 피부의 결합조직인 콜라겐(collagen), 히아루론산(hyaluronic acid), 엘라스틴(elastin), 프로테오글리칸(proteoglycan), 피브로넥틴(fibronectin) 등이 절단되어 심한 과다 염증반응과 피부의 탄력에 지장을 주고 이것이 더 심해질 경우 DNA의 변이에 의해 돌연변이, 암의 유발, 면역기능 저하의 사태에 이르게 된다.Aging can be caused by UV rays, stress, disease conditions, environmental factors, wounds, and aging of free radicals as they age. If this condition is exacerbated, it destroys the antioxidant defenses in vivo and damages cells and tissues. To promote adult disease and aging. In particular, the oxidation of proteins is caused by severe cuts in the connective tissues of collagen, hyaluronic acid, elastin, proteoglycan, fibronectin, and so on, resulting in severe over-inflammatory reaction and skin elasticity. If this worsens, mutations in the DNA can lead to mutations, cancer, and reduced immune function.
그러므로, 신체의 대사 과정 중 발생하는 프리라디칼이나 자외선 조사, 염증반응에 의해 매개되는 프리라디칼을 소거하여 세포막을 보호하고, 또 이미 손상 받 은 세포는 활발한 신진대사에 의해 재생시켜서 세포를 증식시켜야 피부는 빠르게 회복되고 건강한 피부를 유지할 수 있다. 노화에는 프리라디칼 뿐만 아니라 기질 금속단백질 분해효소(Matrix Metalloprotease; MMP)라는 효소가 관여하는데 생체 내에서 콜라겐과 같은 세포외기질의 합성과 분해는 적절하게 조절되나 노화가 진행되면서 그 합성이 감소하며 콜라겐을 분해하는 효소인 기질 금속단백질 분해효소(MMP)의 발현이 촉진되어 피부의 탄력이 저하되고 주름이 형성된다. 그러므로 세포내에서 활성화가 유도되는 MMP 발현을 조절하거나 그 활성을 억제할 수 있는 물질의 개발이 요구되고 있다. 이제까지 화장품의 소재로서 사용된 원료들은 단순히 효소 활성만을 억제하는 것이 대부분이었다. 이에 세포내 자연노화와 광노화에 의해 그 발현이 유도되는 MMP 발현량 및 활성을 조절하고자 하였다.Therefore, it protects the cell membrane by eliminating the free radicals generated by metabolic process of the body, irradiation by UV irradiation and inflammatory reaction, and the already damaged cells should be regenerated by active metabolism to proliferate the skin. Can recover quickly and maintain healthy skin. Aging involves not only free radicals, but also an enzyme called matrix metalloprotease (MMP) .In vivo, the synthesis and degradation of extracellular substrates such as collagen are properly regulated, but their synthesis decreases as aging progresses. Expression of matrix metalloproteinase (MMP), which is an enzyme that degrades, is promoted, thereby decreasing the elasticity of the skin and forming wrinkles. Therefore, there is a need for the development of a substance capable of regulating MMP expression that inhibits activation or inhibiting its activity in cells. Until now, most of the raw materials used as materials for cosmetics simply inhibited enzyme activity. Therefore, we tried to regulate the expression and activity of MMP expression induced by intracellular natural aging and photoaging.
피부색을 결정하는 인자들 가운데에서도 가장 중요한 인자는 색소침착이다.Among the factors that determine skin color, the most important factor is pigmentation.
멜라닌은 자외선을 흡수 또는 산란시켜 자외선으로부터 피부가 손상되는 것을 방지하는데 큰 역할을 하는데, 특별한 최대흡수파장이 없으며 전 영역의 빛을 흡수한다. 또한 활성산소종을 제거하는 기능이 탁월하나, 때로는 멜라닌 자체가 활성산소를 발생시키기도 하며, 멜라닌 구조내의 카테콜이나 퀴논에 의하여 다른 물질을 환원시키거나 산화시키고, 멜라닌 자체가 자유라디칼의 성질을 나타내기도 한다.Melanin plays an important role in absorbing or scattering ultraviolet rays to prevent damage to the skin from ultraviolet rays. There is no special maximum absorption wavelength and it absorbs light in all areas. In addition, it is excellent in removing the active oxygen species, but sometimes melanin itself generates free radicals, and other substances are reduced or oxidized by catechol or quinone in the melanin structure, and melanin itself shows the properties of free radicals. Pray.
멜라닌의 생합성은 아미노산의 일종인 티로신이 멜라닌형성세포의 멜라노좀에서 티로시나제에 의해 산화되어 디하이드록시 페닐알라닌 (dihydroxy phenylalanine)으로 전환되는 것을 시작으로 계속되는 일련의 산화과정을 거쳐 갈 색(pheoelanin), 흑색 (eumelanin)의 중합체로 형성된다. 이러한 생합성 과정은 멜라노좀이라는 특수한 형태의 갈색 세포내 소기관에서 진행되며 멜라닌 과립을 포함한 멜라노좀은 핵 주변 부위에서 수지상 돌기 끝부분으로 이동, 각질세포의 식세포작용에 의해 세포질 내로 이동하고 이들은 각질세포의 핵 주변에 축적된다.The biosynthesis of melanin is a type of amino acid tyrosine, which is oxidized by tyrosinase in melanocytes of melanocytes and converted to dihydroxy phenylalanine. (eumelanin) polymer. This biosynthesis process is carried out in a special type of brown intracellular organelles called melanosomes. Melanosomes, including melanin granules, move from the periphery of the nucleus to the dendritic end of the dendritic projections and into the cytoplasm by the phagocytosis of keratinocytes. Accumulate around the nucleus.
멜라닌의 합성과 멜라노좀의 수, 주위의 각질세포로의 이동은 부분적으로 호르몬과 자외선 등에 영향을 받고 일차적으로 는 유전적인 영향을 크게 받는다. 그 밖에 티로시나제의 발현 및 멜라닌의 합성, 전송에 관여하는 세포내 조절인자인 싸이토카인(cytokine), 구리, 아연, 철 등의 금속 이온 및 인터페론, 프로스타글란딘, 히스타민 등이 관여하는 것으로 알려져 있다.The synthesis of melanin, the number of melanosomes, and the migration to the surrounding keratinocytes are partially influenced by hormones and ultraviolet rays and primarily by genetic effects. In addition, it is known that metal ions such as cytokines, copper, zinc, and iron, interferon, prostaglandin, histamine, etc., which are involved in the expression of tyrosinase, the synthesis and transfer of melanin, are involved.
이미 아스코르빈산(일본특개평 4-9320), 하이드로퀴논(일본특개평-192062), 코직산(일본특개소 56-7710), 알부틴(일본특개평 4-93150) 및 일부의 추출물 등이 티로시나제 저해 활성을 가지고 있어 미백 화장료로 이용되고 있으나 화장품 제형 중에서의 안정성이 낮으므로 분해되어 착색되거나, 이취의 발생, 생체 레벨에서의 효능, 효과의 불분명 및 안전성문제 등으로 그 사용이 제한되고 있는 실정이다. 그리고 티로시나제의 억제 효과는 입증되었으나 실제 생체 레벨과 유사한 실험에서는 그 효과가 낮게 나타난다. 따라서 생체 레벨과 유사한 흑색종 세포 배양에 의한 저해효과 평가가 요구되고 있는 실정이다. 또한 하이드로퀴논은 발암성 물질로 규정되어 화장품에서는 그 사용이 금지 또는 제한되고 있다. 코직산과 아스크르빈산은 매우 불안정한 물질이다. 상기 성분들을 소량 함유한 화장료는 실온에서 수 주일동안 보관하면 갈변 현상이 발생한다.Ascorbic acid (JP-A 4-9320), hydroquinone (JP-A-192062), kojic acid (JP-A-56-7710), arbutin (JP-A 4-93150) and some extracts inhibit tyrosinase. Although it is used as a whitening cosmetic because of its activity, the stability in cosmetic formulations is low, so it is degraded and colored, or its use is limited due to the occurrence of off-flavor, efficacy at the biological level, unclear effect and safety problems. And the inhibitory effect of tyrosinase has been demonstrated, but the effect is low in experiments similar to the actual biologic level. Therefore, the evaluation of the inhibitory effect by melanoma cell culture similar to the biological level is required. In addition, hydroquinone is defined as a carcinogenic substance and its use is prohibited or restricted in cosmetics. Kojic acid and ascorbic acid are very unstable substances. Cosmetics containing a small amount of the above components may cause browning when stored for several weeks at room temperature.
이러한 피부의 문제점을 해결하기 위하여, 최근 여러 화학물질 등에 의한 피부 자극을 줄이기 위해 천연물을 사용한 화장품이 많이 개발되고 있다. 천연 재료는 피부에 부작용이 적을 뿐만 아니라, 최근 천연재료를 이용한 화장품에 대한 소비자들의 호응이 높아짐에 따라 화장품 원료로서 개발가치가 한층 늘어나고 있다. In order to solve the problem of the skin, a lot of cosmetics using natural products have recently been developed to reduce skin irritation caused by various chemicals. Natural materials have less side effects on the skin, and as the consumer's response to cosmetics using natural materials has increased recently, the development value of cosmetics as a raw material for cosmetics is increasing.
본 발명자들은 이제까지 알려지지 않은 여러 천연물들에 있어서 화장품으로의 응용 가능성을 연구한 결과, 쌍떡잎식물 진달래목 진달래과의 천상초를 선정하고 이로부터 추출물을 제조하여, 피부 항산화 효과, 콜라겐합성효과, 피부 잔주름 완화효과, 미백효과, 자외선에 의한 피부손상 완화효과 및 피부자극완화 효과를 측정한 결과, 그 효능이 매우 우수하므로 화장품으로서의 효능을 기대할 수 있다는 것을 발견하게 되었다.The present inventors have studied the possibility of applying to cosmetics in a variety of natural products that have not been known so far, as a result of selecting the Cheoncheoncho of the dicotyledonous Rhododendron and preparing the extract from it, the skin antioxidant effect, collagen synthesis effect, skin wrinkle relief effect As a result of measuring the whitening effect, the skin damage alleviation effect by the ultraviolet ray and the skin stimulation alleviation effect, it was found that the efficacy as a cosmetic product can be expected because it is very excellent.
따라서, 본 발명의 목적은 항산화 효과, 피부노화 방지 효과, 피부주름 개선 효과, 미백 효과, 자외선에 의한 피부자극 완화 효과 및 보습 효과를 갖는 천상초 추출물을 유효성분으로 함유하는 화장료 조성물을 제공하는데 있다.Accordingly, it is an object of the present invention to provide a cosmetic composition containing an extract of Cheoncheoncho having an antioxidant effect, an anti-aging effect, an anti-wrinkle effect, a whitening effect, a skin irritation-reducing effect and a moisturizing effect as an active ingredient.
또한, 본 발명의 다른 목적은 상기 천상초 추출물을 함유하는 화장료 조성물을 인간의 피부에 도포하는 것을 특징으로 하는 화장 방법을 제공하는데 있다.In addition, another object of the present invention is to provide a cosmetic method comprising applying a cosmetic composition containing the cheonsangcho extract to human skin.
본 발명은 항산화 효과, 피부노화 방지 효과, 피부주름 개선 효과, 미백 효과, 자외선에 의한 피부자극 완화 효과 및 보습 효과를 갖는 천상초 추출물을 유효성분으로 함유하는 화장료 조성물을 제공한다.The present invention provides a cosmetic composition containing an extract of Cheoncheoncho as an active ingredient having an antioxidant effect, an anti-aging effect, an anti-wrinkle effect, a whitening effect, a skin irritation-reducing effect and a moisturizing effect.
본 발명의 화장료 조성물에 포함되는 천상초(Rhododendron brachycarpum)는 높고 추운 산꼭대기에서 자라는 늘푸른 떨기나무로 높이는 1∼4m이다. 나무껍질은 잿빛이 섞인 흰색이고 잎은 어긋나지만 가지 끝에서는 5∼7개가 모여 달린다. 꽃은 6∼7월에 피고 10∼20개씩 가지 끝에 총상꽃차례로 달린다. 작은 꽃자루는 붉은빛을 띤 갈색으로서 털이 빽빽이 난다. 화관은 깔때기 모양으로 흰색 또는 연한 노란색이고 안쪽 윗면에 녹색 반점이 있으며 5갈래로 갈라진다. 수술은 10개이고 암술은 1개이다. 씨방에는 갈색 털이 빽빽이 난다. 열매는 삭과로서 타원 모양이며 길이 약 2cm이고 9월에 갈색으로 익는다. Rhododendron brachycarpum included in the cosmetic composition of the present invention is an evergreen evergreen tree growing at high and cold mountain tops, and has a height of 1 to 4 m. The bark is gray with white and leaves are alternated, but at the end of the branch, 5-7 dogs gather together. Flowers bloom in June-July and run in inflorescences at the end of 10-20 branches. Petioles reddish brown with dense hairs. Corollas are funnel-shaped, white or light yellow, with green spots on the inside, with five branches. There are 10 surgeries and 1 pistil. The ovary has dense brown hairs. Fruits are granules, oval-shaped, about 2cm long, ripen brown in September.
천상초는 하늘의 신선이 가꾸는 꽃이라 하여 붙여진 이름으로 만병을 고친다고 만병초, 만년동안 산다고 해서 만년초로 불리기도 한다.Cheonsangcho is a flower made by the freshness of the sky.
본 명세서에서, 용어 '천상초 추출물'은 천상초의 다양한 기관 또는 부분 (예: 잎, 꽃, 뿌리, 줄기, 가지, 껍질 및 종자 등)으로부터 추출하여 얻은 것을 의미하고, 바람직하게는 잎, 줄기, 가지, 껍질 또는 뿌리, 보다 바람직하게는 잎, 가지 또는 뿌리, 가장 바람직하게는 잎으로부터 얻은 추출물을 의미한다.In the present specification, the term 'Cheonchocho extract' means that obtained by extracting from various organs or parts (eg, leaves, flowers, roots, stems, branches, shells and seeds, etc.) of Cheoncheoncho, preferably leaves, stems, branches , Bark or root, more preferably leaves, branches or roots, most preferably extracts obtained from leaves.
본 발명의 천상초 추출물은 당업계에 공지된 통상의 방법에 따라, 즉, 통상적인 온도와 압력의 조건 하에서, 통상적인 용매를 사용하여 제조될 수 있다.The cheonchocho extract of the present invention can be prepared according to conventional methods known in the art, i.e., under conditions of conventional temperature and pressure, using conventional solvents.
본 발명의 천상초 추출물은 정제수, 메탄올, 에탄올, 글리세린, 에틸아세테이트, 부틸렌글리콜, 프로필렌글리콜, 디클로로메탄, 클로로포름, 에틸에테르, 부틸렌글라이콜 및 헥산으로 구성된 군으로부터 선택된 1종 이상의 추출용매를 사용하여 추출되며, 바람직하게는 에탄올 또는 물을 사용하여 추출되며, 보다 바람직하 게는 70%에탄올을 사용하여 추출되는 것을 특징으로 한다. The cheonsangcho extract of the present invention uses at least one extraction solvent selected from the group consisting of purified water, methanol, ethanol, glycerine, ethyl acetate, butylene glycol, propylene glycol, dichloromethane, chloroform, ethyl ether, butylene glycol and hexane Extraction by using, preferably extracted using ethanol or water, more preferably characterized in that the extraction using 70% ethanol.
한편, 본 발명의 천상초 추출물은 상기한 추출 용매뿐만 아니라, 다른 추출 용매를 이용하여도 실질적으로 동일한 효과를 나타내는 추출물이 얻어질 수 있다는 것은 당업자에게 자명한 것이다.On the other hand, it is apparent to those skilled in the art that the cheonsangcho extract of the present invention can be obtained in addition to the above-described extraction solvents, and extracts having substantially the same effects using other extraction solvents.
또한, 본 발명의 추출물은 상술한 추출 용매에 의한 추출물뿐만 아니라, 통상적인 정제 과정을 거친 추출물도 포함한다. 예컨대, 이산화탄소에 의한 감압, 고온에 의한 초임계추출법에 의한 추출, 초음파를 이용한 추출법에 의한 추출, 일정한 분자량 컷-오프 값을 갖는 한외 여과막을 이용한 분리, 다양한 크로마토그래피 (크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)에 의한 분리 등, 추가적으로 실시된 다양한 정제 방법을 통해 얻어진 활성 분획도 본 발명의 추출물에 포함되는 것이다.In addition, the extract of the present invention includes not only the extract by the above-described extraction solvent, but also the extract that has undergone a conventional purification process. For example, decompression by carbon dioxide, extraction by supercritical extraction by high temperature, extraction by ultrasonic extraction, separation using ultrafiltration membranes with constant molecular weight cut-off values, various chromatography (size, charge, hydrophobicity or affinity) The active fraction obtained through various purification methods additionally carried out, such as separation by sex)) is also included in the extract of the present invention.
또한, 본 발명의 천상초 추출물은 상온에서 냉침, 가열 여과하여 얻어진 액상물, 추가로 용매를 감압농축 또는 동결건조하여 얻을 수도 있다. In addition, the cheonsangcho extract of the present invention may be obtained by cold condensation at room temperature, a liquid obtained by heat filtration, and further by concentrating the solvent under reduced pressure or lyophilization.
또한, 본 발명의 천상초 추출물은 화장료 조성물 전체에 대해서 0.001-30.0중량% 함유되며, 바람직하게는 0.1-10.0 중량% 함유되는 것을 특징으로 한다. 상기 추출물의 함량이 0.001중량% 미만인 경우에는 피부개선 효과가 나타나지 않으며, 30.0중량% 이상인 경우에는 함유량 증가에 대한 효과 증대 정도가 미미하며, 제형상의 안전 및 안정성에 문제가 있으며 경제적이지도 못하다.In addition, the cheonsangcho extract of the present invention is contained 0.001-30.0% by weight, preferably 0.1-10.0% by weight based on the entire cosmetic composition. If the content of the extract is less than 0.001% by weight does not appear to improve the skin, when more than 30.0% by weight of the effect of increasing the effect of the content is insignificant, there is a problem in the safety and stability of the formulation and economical.
본 발명에 따르면, 천상초 추출물은 항산화 효과(실험예 1 및 2), MMP-1 생성 억제효과(실험예 3), 자외선에 의한 MMP-1 생성 억제효과(실험예 4), 콜라겐 합성증진효과(실험예 5), 멜라닌 생성 억제효과(실험예 6), 자외선 조사에 의한 세포독성 완화 효과(실험예 7), 자외선 조사에 의한 염증성 사이토카인 발현 억제효과(실험예 8), 피부탄력 개선효과(실험예 9), 보습효과(실험예 10)가 뛰어나다.According to the present invention, the extract of Cheonsangchocho has antioxidant effect (Experimental Examples 1 and 2), MMP-1 production inhibitory effect (Experimental Example 3), MMP-1 production inhibitory effect by ultraviolet light (Experimental Example 4), collagen synthesis promoting effect ( Experimental Example 5), melanin production inhibitory effect (Experimental Example 6), cytotoxicity mitigating effect by ultraviolet irradiation (Experimental Example 7), inflammatory cytokine expression inhibitory effect (Experimental Example 8), skin elasticity improvement effect ( Experimental Example 9) and excellent moisturizing effect (Experimental Example 10).
따라서, 이러한 다양한 기능을 가진 천상초 추출물을 유효성분으로 포함하는 본 발명의 화장료 조성물은 항산화 효과, 피부노화 방지 효과, 피부주름 개선 효과, 미백 효과, 자외선에 의한 피부자극 완화 효과 및 보습 효과를 갖는다. Therefore, the cosmetic composition of the present invention comprising the extract of Cheoncheoncho with various functions as an active ingredient has an antioxidant effect, skin anti-aging effect, skin wrinkle improvement effect, whitening effect, skin irritation relief effect and moisturizing effect.
본 발명의 화장료 조성물에 포함되는 성분은 유효 성분으로서 상기 유효성분 이외에 화장품 조성물에 통상적으로 이용되는 성분들을 포함하며, 예컨대 항산화제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 그리고 담체를 포함한다.Ingredients included in the cosmetic composition of the present invention as an active ingredient includes components conventionally used in cosmetic compositions in addition to the active ingredient, for example, conventional auxiliaries such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavors, And carriers.
본 발명의 화장료 조성물은 당 업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클렌징, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 유연 화장수, 영양 화장수, 영양 크림, 마사지 크림, 에센스, 아이 크림, 클렌징 크림, 클렌징 포옴, 클렌징 워터, 팩, 스프레이 또는 파우더의 제형으로 제조될 수 있다.The cosmetic composition of the present invention may be prepared in any formulation commonly prepared in the art, for example, solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing , Oils, powder foundations, emulsion foundations, wax foundations and sprays, and the like, but are not limited thereto. More specifically, it may be prepared in the form of a flexible lotion, nutrition lotion, nutrition cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray or powder.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, animal oils, vegetable oils, waxes, paraffins, starches, trachants, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicas, talc or zinc oxide may be used as carrier components. Can be.
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used, in particular in the case of a spray, additionally chlorofluorohydrocarbon, propane Propellant such as butane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the present invention is a solution or emulsion, a solvent, solubilizer or emulsifier is used as the carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 Fatty acid esters of, 3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소 결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the present invention is a suspension, liquid carrier diluents such as water, ethanol or propylene glycol, suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol esters and polyoxyethylene sorbitan esters, and microcrystals are used as carrier components. Soluble cellulose, aluminum metahydroxy, bentonite, agar or tracant and the like can be used.
본 발명의 제형이 계면-활성제 함유 클렌징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is a surfactant-containing cleansing, the carrier component is aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide. Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.
또한, 본 발명은 본 발명의 천상초 추출물을 함유하는 화장료 조성물을 인간의 피부에 도포하는 것을 특징으로 하는 화장방법을 제공한다.In addition, the present invention provides a cosmetic method comprising applying to the human skin a cosmetic composition containing the cheonsangcho extract of the present invention.
본 발명의 화장 방법은 본 발명의 화장료 조성물을 인간의 피부에 도포하는 모든 화장 방법을 일컫는다. 즉, 화장료 조성물을 피부에 도포하는 당업계에 공지된 모든 방법이 본 발명의 화장 방법에 속한다.The cosmetic method of the present invention refers to all cosmetic methods for applying the cosmetic composition of the present invention to human skin. That is, all the methods known in the art for applying the cosmetic composition to the skin belong to the cosmetic method of the present invention.
본 발명의 화장료 조성물은 단독 또는 중복 도포하여 사용하거나, 본 발명 이외의 다른 화장료 조성물과 중복 도포하여 사용할 수 있다. 또한 본 발명에 따른 피부 보호 효과가 우수한 화장료 조성물은 통상적인 사용방법에 따라 사용될 수 있으며, 사용자의 피부 상태 또는 취향에 따라 그 사용횟수를 달리할 수 있다.The cosmetic composition of the present invention may be used alone or in duplicate, or may be used in combination with other cosmetic compositions other than the present invention. In addition, the cosmetic composition with excellent skin protection effect according to the present invention can be used according to a conventional method of use, the number of times of use can be varied according to the user's skin condition or taste.
본 발명의 화장료 조성물이 비누, 계면활성제 함유 클렌징 또는 계면활성제 비함유 클렌징 제형일 경우, 피부에 도포한 후 닦아내거나 떼거나 물로 씻어낼 수도 있다. 구체적인 예로서, 상기 비누는 액상비누, 가루비누, 고형비누 및 오일비누이며, 상기 계면활성제 함유 클린징 제형은 클렌징폼, 클렌징 워터, 클렌징 수건 및 클렌징 팩이며, 상기 계면활성제 비함유 클렌징 제형은 클렌징크림, 클렌징 로션, 클렌징 워터 및 클렌징 겔이며, 이에 한정되는 것은 아니다.When the cosmetic composition of the present invention is a soap, surfactant-containing cleansing or surfactant-free cleansing formulation, it may be wiped off, peeled off or washed with water after application to the skin. As a specific example, the soap is liquid soap, powdered soap, solid soap and oil soap, the surfactant-containing cleansing formulation is a cleansing foam, cleansing water, cleansing towels and cleansing pack, the surfactant-free cleansing formulation is a cleansing cream , Cleansing lotion, cleansing water and cleansing gel, but are not limited thereto.
본 발명의 천상초 추출물을 포함하는 화장료 조성물을 인간의 피부에 도포하는 화장방법을 수행하면, 피부의 노화 방지, 주름개선 효과, 미백 효과, 보습 효과, 자외선에 의한 피부자극 완화 효과를 얻을 수 있다.When the cosmetic method including the cheonsangcho extract of the present invention is applied to the skin of a human, the anti-aging, anti-wrinkle effect, whitening effect, moisturizing effect, and skin irritation relief effect may be obtained.
본 발명의 천상초 추출물은 항산화 효과, MMP 저해 효과, 자외선 조사에 의한 MMP 발현 조절효과, 잔주름 개선효과 등 우수한 항노화 효과와 자외선 조사 후 야기되는 피부자극을 완화시켜 주는 효과를 나타내었다. 또한, 천상초 추출물은 기미, 주근깨 및 피부 색소 침착의 원인이 되는 물질인 멜라닌 생성억제 효과 등의 미백작용을 나타내었다. 따라서, 이러한 천상초 추출물을 함유하는 화장료 조성물은 항산화 효과와 함께 콜라겐 분해효소 활성 조절 효과, 피부 잔주름 개선 효과, 항염증, 미백 등 우수한 피부 개선 효과를 가짐을 알 수 있다.The extract of Cheoncheoncho of the present invention showed an excellent anti-aging effect such as antioxidant effect, MMP inhibitory effect, MMP expression control effect by UV irradiation, fine wrinkle improvement effect and alleviating skin irritation caused by UV irradiation. In addition, the cheonsangcho extract showed a whitening effect such as melanin production inhibitory effect, which is a substance causing blemishes, freckles and skin pigmentation. Therefore, it can be seen that the cosmetic composition containing the extract of Cheoncheoncho has an excellent skin improvement effect such as collagen degrading enzyme activity control effect, skin fine wrinkle improvement effect, anti-inflammatory, whitening and the like with antioxidant effect.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다는 것은 당업계에서 통상의 지식을 가진 자에 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are only for illustrating the present invention in more detail, it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples in accordance with the gist of the present invention. .
제조예 1: 천상초 추출물의 제조Preparation Example 1 Preparation of Cheonsangcho Extract
세절하여 음건한 천상초의 잎을 70%(V/V) 에탄올 수용액으로 5시간씩 3회 환류추출하고 냉침한 후, 와트만(Whatman) #5 여과지로 여과하였다. 여과된 추출물을 50℃ 이하에서 감압농축 및 동결건조하였다. 감압농축물 및 동결건조물이 1%가 되게 50% 부틸렌글리콜용액에 분산/용해하여 천상초 추출물을 제조하였다.The dried and dried leaves of Cheoncheoncho were refluxed three times for 5 hours with an aqueous 70% (V / V) ethanol solution, and then cooled and filtered through Whatman # 5 filter paper. The filtered extract was concentrated under reduced pressure and lyophilized at 50 ° C or lower. The extract was prepared by dispersing / dissolving in a 50% butylene glycol solution under reduced pressure and freeze-dried to 1%.
실험예 1: NBT법을 이용한 항산화 효과 측정 실험Experimental Example 1 Experiment of Measuring Antioxidant Effect Using NBT Method
본 실험예는 제조예 1에서 수득한 천상초 추출물의 항산화 효과를 확인하기 위해 실험실 조건에서 다른 항산화제 즉, 레티놀(retinol)과 BHT(Butylated Hydroxytoluene)를 비교샘플로 하였으며, NBT법을 이용하여 항산화 활성을 측정하였다.In order to confirm the antioxidant effect of the extract of Cheoncheoncho obtained in Preparation Example 1, this experiment was compared with other antioxidants, such as retinol and BHT (Butylated Hydroxytoluene) under laboratory conditions. Was measured.
항산화 효과를 측정하기 위해서 크산틴과 크산틴옥시다제에 의해 생성되는 활성산소를 NBT법에 의해 측정하고 피검물질이 활성산소를 제거하는 효과, 즉 활성산소 소거효과를 평가한다. 크산틴과 크산틴옥시다제에 의해 활성산소를 생성시킨다. 이 활성산소가 니트로블루테트라졸리움(Nitro Blue Tetrazolium;NBT)과 반응하여 이것에 의해 생성되는 청색을 파장 560nm에서 측정하는 것으로 활성산소 소거율을 측정한다.In order to measure the antioxidant effect, the active oxygen produced by xanthine and xanthine oxidase is measured by the NBT method, and the effect of the test substance removing the active oxygen, that is, the active oxygen scavenging effect, is evaluated. Free radicals are produced by xanthine and xanthine oxidase. This active oxygen reacts with Nitro Blue Tetrazolium (NBT) to measure the active oxygen scavenging rate by measuring the blue color produced by this at a wavelength of 560 nm.
측정방법으로서As a measuring method
1. 0.05M Na2CO3 ------------------------------------ 2.4ml0.05M Na 2 CO 3 ------------------------------------ 2.4ml
2. 3mM 크산틴 용액---------------------------------- 0.1ml2.3mM xanthine solution ---------------------------------- 0.1ml
3. 3mM EDTA 용액------------------------------------ 0.1ml3.3mM EDTA Solution ------------------------------------ 0.1ml
4. BSA 용액----------------------------------------- 0.1ml4.BSA solution ---------------------------------------- 0.1ml
5. 0.72mM NBT 용액---------------------------------- 0.1ml5.0.72 mM NBT solution ---------------------------------- 0.1ml
6. 크산틴 옥시다제 용액----------------------------- 0.1ml6.Xanthine Oxidase Solution ----------------------------- 0.1ml
7. 6mM CuCl2 용액----------------------------------- 0.1ml7.6 mM CuCl 2 solution ----------------------------------- 0.1ml
① 바이엘병에 1,2,3,4,5를 가하고 여기에 시료용액 0.1ml을 첨가하고 25℃에서 10분간 방치한다.① Add 1,2,3,4,5 to Bayer's bottle and add 0.1ml of sample solution to it and leave at 25 ℃ for 10 minutes.
② 6을 가하여 빨리 교반하고 25℃에서 20분간의 배양을 개시한다.② Add 6 and stir quickly, and start incubation for 20 minutes at 25 ℃.
③ 그 후 7을 가하여 반응을 정지시키고 560nm에서의 흡광도 St를 측정한다.③ After that, add 7 to stop the reaction and measure the absorbance St at 560nm.
④ 공시험은 시료용액 대신에 증류수를 사용한 것을 상기와 똑같이 조작해 흡광도 Bt를 측정한다.④ For the blank test, measure the absorbance Bt by using distilled water instead of the sample solution as above.
⑤ 역시, 시료용액의 블랭크(Blank)는 6 대신에 증류수를 사용해 똑같이 조작하여 흡광도 Bo를 측정한다.⑤ Also, the blank of the sample solution is operated in the same manner using distilled water instead of 6 to measure the absorbance Bo.
활성산소 소거율은 수학식 1에 의하여 산출하였으며, 결과는 표 1에 나타내었다.The reactive oxygen scavenging ratio was calculated by Equation 1, and the results are shown in Table 1.
St : 시료용액의 효소 반응 후의 560nm에서의 흡광도St: absorbance at 560 nm after enzyme reaction of sample solution
Bt : 공시험용액의 효소 반응 후의 560nm에서의 흡광도Bt: absorbance at 560 nm after enzymatic reaction of blank test solution
So : 시료용액의 효소 무첨가시 반응전의 560nm에서의 흡광도So: absorbance at 560 nm before reaction without enzyme addition of sample solution
Bo : 공시험용액의 효소 무첨가시 반응전의 560nm에서의 흡광도Bo: absorbance at 560 nm before reaction without enzyme in blank test solution
상기 표 1의 결과에서 보는 바와 같이, 0.01% 농도에서 시험한 시료 모두에서 우수한 항산화 효과를 확인할 수 있었다. 천상초 추출물은 레티놀 및 BHT와 유사하거나 훨씬 우수한 항산화력을 가지고 있음이 확인되었다.As shown in the results of Table 1, all of the samples tested at a concentration of 0.01% was able to confirm the excellent antioxidant effect. It was found that the extract of Cheonsangcho had similar or better antioxidant power than retinol and BHT.
실험예Experimental Example 2: 2: DPPHDPPH 법을 이용한 항산화 효과 측정 실험Antioxidant Effect Measurement Experiment
본 실험예는 제조예 1에서 수득한 천상초 추출물의 항산화 효과를 측정하기 위해 실험실 조건에서 비타민 C와 같은 항산화제를 비교샘플로 하여 DPPH법을 이용하여 항산화 활성을 측정하였다.In this Experimental Example, to measure the antioxidant effect of the extract of Cheonsangcho obtained in Preparation Example 1, the antioxidant activity such as vitamin C was compared in the laboratory conditions and the antioxidant activity was measured using the DPPH method.
DPPH법은 DPPH(2,2-Di(4-tert-octylphenyl)-1-picrylhydrazyl) 프리라디칼이라는 유리기를 사용하여 환원력에 의한 항산화 활성을 측정한다. 피검물질에 의해 DPPH가 환원되어 흡광도가 감소하는 정도를 공시험액의 흡광도와 비교하여 파장 560nm에서 자유라디칼 소거율을 측정한다.The DPPH method measures the antioxidant activity by reducing power using a free group called DPPH (2,2-Di (4-tert-octylphenyl) -1-picrylhydrazyl) free radical. The free radical scavenging rate is measured at a wavelength of 560 nm by comparing the degree to which the DPPH is reduced by the test substance to reduce the absorbance.
사용한 시약으로서는 2,2-Di(4-tert-octylphenyl)-1-picrylhydrazyl 프리라디칼(Aldrich Chem. Co., MW=618.76)0.1mM 용액으로서 61.88mg을 메탄올에 용해하여 100ml로 한다.As a reagent used, 2,2-Di (4-tert-octylphenyl) -1-picrylhydrazyl free radical (Aldrich Chem. Co., MW = 618.76) 0.1 mM solution was dissolved in methanol to make 100 ml.
측정방법으로서As a measuring method
① 96-웰 플레이트에 0.1mM DPPH 용액 0.15ml에 시료용액 0.15ml를 가하여 빨리 교반하고 25℃에서 10분간의 배양을 개시한다.① Add 0.15ml of sample solution to 0.15ml of 0.1mM DPPH solution in 96-well plate, stir rapidly, and incubate for 10 minutes at 25 ℃.
② 그 후 560nm에서의 흡광도 St를 측정한다.(2) Then measure the absorbance St at 560nm.
③ 공시험은 시료용액 대신에 증류수를 사용한 것을 상기와 똑같이 조작해 흡광도 Bt를 측정한다.③ In the blank test, measure the absorbance Bt by using distilled water instead of the sample solution as above.
④ 역시, 시료용액의 블랭크(Blank)는 0.1mM DPPH 용액 대신에 메탄올을 사용해 똑같이 조작하여 흡광도 Bo를 측정한다.④ Again, the blank of the sample solution was operated in the same manner using methanol instead of the 0.1 mM DPPH solution to measure the absorbance Bo.
효과의 결과는 수학식 2에 의하여 산출하였으며, 결과는 표 2에 나타내었다.The result of the effect was calculated by Equation 2, the results are shown in Table 2.
St : 시료용액의 자유라디칼 소거 후의 560nm에서의 흡광도St: absorbance at 560 nm after free radical scavenging of sample solution
Bt : 공시험용액의 자유라디칼 소거 후의 560nm에서의 흡광도Bt: absorbance at 560 nm after free radical scavenging of blank test solution
So : 시료용액의 자유라디칼 무첨가시 반응 전의 560nm에서의 흡광도So: Absorbance at 560 nm before reaction without free radicals in sample solution
Bo : 공시험용액의 자유라디칼 무첨가시 반응 전의 560nm에서의 흡광도Bo: absorbance at 560 nm before reaction without free radicals in blank test solution
상기 표 2의 결과에서 보는 바와 같이, 본 발명의 천상초 추출물은 0.01% 농도에서 비타민 C와 유사한 우수한 자유라디칼 소거율을 갖고 있음이 확인되었다.As shown in the results of Table 2, it was confirmed that the Cheoncheoncho extract of the present invention has an excellent free radical scavenging ratio similar to vitamin C at 0.01% concentration.
실험예Experimental Example 3. 3. MMPMMP -1 생성 억제 효과-1 suppression effect
인간 정상 피부세포인 섬유아세포(한국 세포주 은행, 대한민국)를 48-웰 마이크로 플레이트(Nunc, 덴마크)에 각 웰당 1× 106 세포가 되도록 접종하고, DMEM 배지(Sigma, 미합중국) 및 37℃의 조건에서 24시간 동안 배양한 후 상기 제조예 1의 천상초 추출물을 최종 농도 100 ㎍/㎖로 첨가한 무혈청 DMEM 배지 및 대조군으로 천상초 추출물이 포함되지 않은 무혈청 DMEM 배지에서 48시간 동안 추가로 배양하였다. 배양 후, 각 웰의 상층액을 모아 MMP-1 분석 킷트(Amersham, 미합중국)를 이용하여 새로 합성된 MMP-1의 양(ng/㎖)을 측정하고, 하기 수학식 3에 따라 MMP-1 생성 억제율을 계산하였으며, 그 결과는 표 3에 나타내었다. 이때, MMP-1 생성 억제율의 양성 대조군으로 TGF-β(10ng/ml, Roche, 미합중국)을 사용하였다. Fibroblasts (Korean Cell Line Bank, Korea), which are human normal skin cells, were seeded in 48-well microplates (Nunc, Denmark) at 1 × 10 6 cells per well, and treated with DMEM medium (Sigma, USA) and 37 ° C. After culturing for 24 hours at the serum-free DMEM medium was added to the final concentration of 100 ㎍ / ㎖ Cheonchocho extract of Preparation Example 1 and further incubated for 48 hours in a serum-free DMEM medium containing no cheonchocho extract as a control. After incubation, the supernatant of each well was collected and the amount of ng / ml newly synthesized MMP-1 was measured using an MMP-1 assay kit (Amersham, USA), and MMP-1 production was performed according to Equation 3 below. Inhibition rate was calculated and the results are shown in Table 3. At this time, TGF-β (10 ng / ml, Roche, United States) was used as a positive control of MMP-1 production inhibition rate.
상기 표 3의 결과에서 보는 바와 같이, 본 발명의 천상초 추출물은 TGF-β 보다 우수한 정도의 MMP-1 생성 억제율을 보여주었다.As shown in the results of Table 3, the extract of Cheoncheoncho of the present invention showed a higher MMP-1 production inhibition rate than TGF-β.
실험예Experimental Example 4. 4. 천상초Cheonsangcho 추출물의 자외선 유도에 의한 By UV induction of extract MMPMMP -1 생성 억제 효과-1 suppression effect
일반적으로 MMP-1은 자외선에 의해 그 양이 증가되는 것으로 알려져 있다. 따라서 본 발명의 천상초 추출물이 자외선에 의해 생성이 증가되는 MMP-1의 양을 억제하는지를 알아보고자 실험을 실시하였다. 실험은 시료 처리에 앞서 UVA를 일정량 처리하는 것을 제외하고는 실험예 3과 동일하게 실시하였다. 본 실험에 사용한 천상초 추출물은 제조예 1의 추출물을 사용하였으나, 본 실험의 결과가 이에 한정되는 것은 아니다. MMP-1 생성 억제율은 상기 수학식 3에 따라 계산하였으며, 그 결과는 하기 표 4에 나타내었다.In general, MMP-1 is known to increase its amount by ultraviolet light. Therefore, the experiment was performed to determine whether the extract of Cheoncheoncho of the present invention inhibits the amount of MMP-1, which is increased by UV light. The experiment was performed in the same manner as in Experiment 3 except that a certain amount of UVA was treated before sample treatment. Cheonsangcho extract used in this experiment was used the extract of Preparation Example 1, but the results of this experiment is not limited thereto. MMP-1 production inhibition rate was calculated according to Equation 3, the results are shown in Table 4 below.
상기 표 4의 결과에서 보는 바와 같이, 본 발명의 천상초 추출물의 자외선 유도 후의 MMP-1 생성 억제율은 TGF-β보다 더 우수하였다.As shown in the results of Table 4, the inhibition rate of MMP-1 production after UV-induction of the Cheoncheoncho extract of the present invention was better than TGF-β.
실험예Experimental Example 5. 5. 천상초Cheonsangcho 추출물의 콜라겐 합성 증진 효과 Enhancement of Collagen Synthesis by Extracts
인간 정상 상피세포인 섬유아세포를 48-웰 마이크로 플레이트에 각 웰당 1 x 106 세포가 되도록 접종하고, DMEM 배지에서 24시간 동안 배양하였다. 상기 제조예 1의 천상초 추출물을 최종농도 100 ㎍/㎖로 첨가한 무혈청 DMEM 배지(실험군) 및 천상초 추출물이 포함되지 않은 무혈청 DMEM 배지(대조군)를 48시간 동안 추가로 배양하였다. 배양 후, 각 웰의 상층액을 모아 콜라겐 키트(Takara, 일본)를 이용하여 프로콜라겐 (procollagen) 타입 I C-펩타이드 (PICP) 양을 측정하여 ng/㎖ 환산하였으며, 이로 합성된 콜라겐 양을 측정하였다. 본 실험의 양성대조군으로는 TGF-β를 사용하였다. 콜라겐 생합성 증가율은 하기 수학식 4에 따라 계산하였으며, 그 결과는 표 5에 나타내었다. Fibroblasts, human normal epithelial cells, were seeded in 48-well microplates at 1 × 10 6 cells per well and incubated in DMEM medium for 24 hours. Serum-free DMEM medium (experimental group) and the serum-free DMEM medium (control group) not containing the extract of Cheoncheoncho were added to the cheonsangcho extract of Preparation Example 1 at a final concentration of 100 μg / ml for 48 hours. After incubation, the supernatant of each well was collected and measured in ng / ml by measuring the amount of procollagen (procollagen) type I C-peptide (PICP) using a collagen kit (Takara, Japan), and the amount of collagen synthesized therefrom was measured. It was. TGF-β was used as a positive control in this experiment. Collagen biosynthesis increase rate was calculated according to the following equation (4), the results are shown in Table 5.
상기 표 5의 결과에서 보는 바와 같이, 본 발명의 천상초 추출물의 콜라겐 합성 증진 효과는 TGF-β에 비해 월등히 높게 나타났다.As shown in the results of Table 5, the collagen synthesis enhancement effect of the extract of Cheoncheoncho of the present invention was significantly higher than TGF-β.
실험예Experimental Example 6: B16F1 멜라닌형성세포를 이용한 멜라닌 생성 억제효과 측정 6: Determination of Melanogenesis Inhibitory Effect Using B16F1 Melanogenic Cells
제조예 1에서 수득한 천상초 추출물의 미백효과를 확인하기 위해 B16F1 멜라닌형성세포에 대한 멜라닌 생성 억제 정도를 보고 미백효과를 판단하였다. 본 실험예에 사용된 B16F1 멜라닌형성세포는 마우스에서 유래한 세포균주이며, 멜라닌이라는 흑색색소를 분비하는 세포이다. 이 세포의 인공배양 중에 시료를 처리하여 멜라닌 흑색색소가 감소하는 정도를 비교 평가하였다. 본 실험예에 사용된 B16F1 멜라닌형성세포는 ATCC(American Type Culture Collection)로부터 분양받아 사용하였다.In order to confirm the whitening effect of the extract of Cheonsangcho obtained in Preparation Example 1, the whitening effect was determined by looking at the degree of inhibition of melanin production on B16F1 melanocytes. B16F1 melanocytes used in this experiment is a cell strain derived from the mouse, and secreted a black pigment called melanin. Samples were treated during the artificial culture of these cells to evaluate the degree of melanin black pigment reduction. B16F1 melanocytes used in the present experiment was used by receiving from the American Type Culture Collection (ATCC).
B16F1 멜라닌형성세포의 멜라닌 생합성 억제효과 측정은 다음과 같이 행하였다. B16F1 멜라닌형성 세포를 6웰 플레이트에 각 웰당 2 X 106 농도로 분주하고 세포를 부착시킨 후 독성을 유발하지 않는 농도로 시료를 처리하여 72시간 동안 배양하였다. 72시간 배양 후 세포를 트립신-EDTA로 떼어 낸 후 세포수를 측정한 다음 원심분리하여 세포를 회수하였다. 세포내 멜라닌의 정량은 로탄(Lotan: Cancer Res., 40: 3345-3350, 1980)의 방법을 약간 변형하여 실시하였다. 셀 펠릿을 PBS로 1회 세척한 후 균질화 버퍼액(50 mM 소듐 포스페이트, pH 6.8, 1% Triton X-100, 2 mM PMSF) 1ml를 첨가하여 5분간 와류하여 세포를 파쇄하였다. 원심분리 (3,000 rpm, 10분)하여 얻은 세포 여액에 1N NaOH(10% DMSO)를 첨가하여 추출된 멜라닌을 용해한 후 마이크로 플레이트 판독기로 405nm에서 멜라닌의 흡광도를 측정한 다음 멜라닌을 정량하여 시료의 멜라닌 생성저해율(%)을 측정하였다. B16F1 멜라닌형성세포의 멜라닌 생성저해율(%)은 수학식 5에 의하여 계산하였으며, 그 값을 하기 표 6에 나타내었다. IC50 값은 멜라닌 생성을 50% 저해하는 물질의 농도이다. 천상초 추출물의 멜라닌 생성저해율 정도를 확인하기 위해 양성 대조군으로서 하이드로퀴논 및 알부틴을 사용하여 동일하게 실험하였다.The melanin biosynthesis inhibitory effect of B16F1 melanogenesis cells was measured as follows. B16F1 melanocytes were dispensed in 6-well plates at a concentration of 2 X 10 6 per well, and the cells were attached and incubated for 72 hours by treating the sample at a concentration that does not cause toxicity. After 72 hours of incubation, the cells were detached with trypsin-EDTA, the cell number was measured, and the cells were recovered by centrifugation. Quantification of intracellular melanin was carried out with a slight modification of the method of Rotan: Cancer Res., 40: 3345-3350, 1980. The cell pellet was washed once with PBS, and then 1 ml of homogenization buffer solution (50 mM sodium phosphate, pH 6.8, 1% Triton X-100, 2 mM PMSF) was added and vortexed for 5 minutes to disrupt cells. Melanin was extracted by adding 1N NaOH (10% DMSO) to the cell filtrate obtained by centrifugation (3,000 rpm, 10 minutes), and then the absorbance of melanin was measured at 405 nm with a microplate reader. Production inhibition rate (%) was measured. Melanin inhibition rate (%) of B16F1 melanogenesis cells was calculated by Equation 5, the values are shown in Table 6 below. IC 50 value is the concentration of substance that inhibits melanin production by 50%. In order to confirm the degree of melanin inhibition rate of the extract of Cheonsangcho extract, the same experiment was conducted using hydroquinone and arbutin as positive controls.
A : 시료를 첨가하지 않은 웰의 멜라닌 양A: Melanin amount in wells without sample
B : 시료를 첨가한 웰의 멜라닌 양B: Melanin amount in the wells to which the sample was added
상기 표 6의 결과에서 보는 바와 같이, 본 발명의 천상초 추출물의 멜라닌 합성 저해효과(IC50)는 0.06%로 나타났으며, 기존의 미백제인 하이드로퀴논, 알부틴 등에 비해 유사하거나 우수한 효과를 나타내었다.As shown in the results of Table 6, the melanin synthesis inhibitory effect (IC 50 ) of the cheonsangcho extract of the present invention was found to be 0.06%, showing a similar or superior effect compared to the existing whitening agents hydroquinone, arbutin and the like.
실함예Example 7: 자외선 조사에 의한 세포독성 완화 효과 7: Reduction of cytotoxicity by UV irradiation
본 실시예는 제조예 1에서 수득한 천상초 추출물의 자외선 조사에 의한 세포독성의 완화효과를 평가하기 위하여 실시되었다. 섬유아세포(fibroblast)를 24-웰 시험 플레이트에 1X105개씩 넣고 24시간 동안 부착시켰다. 각 웰을 PBS로 1회 세척하고 각 웰에 500㎕의 PBS를 넣었다. 이 섬유아세포에 자외선 B(UVB) 램프(Model : F15T8, UV B15W, Sankyo Dennki사, Japan)를 이용하여 자외선 10mJ/㎠를 조사한 후 PBS를 덜어내고 세포배양 배지(DMEM에 10%FBS가 첨가된 것) 1㎖을 첨가하였다. 여기에 평가하고자 하는 천상초 추출물을 처리한 후 24시간동안 배양하였다. 24시간이 지나면 배지를 제거하고, 각 웰당 세포배양 배지 500㎕ 배지와 MTT 용액(2.5㎎/㎖) 60㎕를 넣은 후 2시간 동안 37℃ CO2 배양기에서 배양하였다. 배지를 제거하고 이소프로판올-HCl(0.04N)을 500㎕씩 넣어주었다. 5분간 진탕하여 세포를 용해시키고 상등액 100㎕씩을 96-웰 시험 플레이트에 옮긴 후, 마이크로플레이트 판독기를 사용해 565 nm에서 흡광도를 측정하였다. 하기 수학식 6에 의해 세포생존율(%)을 측정하고 자외선에 의한 세포독성 완화율은 수학식 7에 의하여 계산하였다.This example was carried out to evaluate the mitigating effect of cytotoxicity by ultraviolet irradiation of the Cheoncheoncho extract obtained in Preparation Example 1. Fibroblasts (fibroblasts) were placed in a 24-well test plate each 5 × 1 × 10 attached for 24 hours. Each well was washed once with PBS and 500 μl of PBS was added to each well. The fibroblasts were irradiated with UV 10mJ / cm 2 using an ultraviolet B (UVB) lamp (Model: F15T8, UV B15W, Sankyo Dennki, Japan), and then PBS was removed and 10% FBS was added to the cell culture medium (DMEM). 1 ml) was added. After treating the Cheoncheoncho extract to be evaluated therein, it was incubated for 24 hours. After 24 hours, the medium was removed, and 500 μl of cell culture medium and 60 μl of MTT solution (2.5 mg / ml) were added to each well, followed by incubation in a 37 ° C. CO 2 incubator for 2 hours. The medium was removed, and 500 μl of isopropanol-HCl (0.04N) was added thereto. After shaking for 5 minutes, the cells were lysed and 100 μl of the supernatant was transferred to a 96-well test plate, and the absorbance was measured at 565 nm using a microplate reader. The cell viability (%) was measured by the following Equation 6, and the cytotoxicity relaxation rate by ultraviolet rays was calculated by the following Equation 7.
Bo : 세포배양배지 만을 발색 반응한 웰의 565 nm 흡광도Bo: 565 nm absorbance of wells that only developed cell culture media
Bt : 시료를 처리하지 않은 웰을 발색 반응한 웰의 565 nm 흡광도Bt: 565 nm absorbance of the wells that developed the colorless reaction wells
St : 시료를 처리한 웰을 발색 반응한 웰의 565 nm 흡광도St: 565 nm absorbance of the wells that reacted the sample treated wells
Bo : 자외선 조사하지 않고 시료 처리하지 않은 웰의 세포 생존율Bo: cell viability of wells without UV irradiation and no sample treatment
Bt : 자외선 조사하고 시료를 처리하지 않은 웰의 세포생존율Bt: cell viability of wells that were not irradiated with UV light
St : 자외선 조사하고 시료를 처리한 웰의 세포생존율St: Cell survival rate of wells treated with UV
상기 표 7의 결과에서 보는 바와 같이, 본 발명의 천상초 추출물은 자외선에 의한 세포 독성을 0.013% 농도에서 45% 억제하며,0.025%에서는 63%나 억제하므로, 자외선에 의한 세포독성을 효과적으로 방어함을 알 수 있었다.As shown in the results of Table 7, the Cheoncheoncho extract of the present invention inhibits cytotoxicity caused by ultraviolet light at 45% at 0.013% concentration, and inhibits 63% at 0.025%, effectively preventing cytotoxicity caused by ultraviolet light. Could know.
실험예Experimental Example 8: 자외선 조사에 의한 염증성 사이토카인 발현 억제효과 8: Inhibitory Effect of Inflammatory Cytokine Expression by Ultraviolet Irradiation
본 실시예는 제조예 1에서 수득한 천상초 추출물의 자외선 조사에 의해 발현되는 염증성 사이토카인 발현 억제효과를 평가하기 위하여 사람의 표피조직에서 분리한 섬유아세포(Fibroblast)를 24-웰 시험 플레이트에 5X104개씩 넣고 24시간 동안 부착시켰다. 각 웰을 PBS로 1회 세척하고 각 웰에 500㎕의 PBS를 넣었다. 이 섬유아세포에 자외선B(UVB) 램프(Model : F15T8, UV B 15W, Sankyo Dennki사, Japan)를 이용하여 자외선 10mJ/㎠를 조사한 후 PBS를 덜어내고 세포배양 배지(DMEM에 FBS가 첨가되지 않은 배지) 350㎕를 첨가하였다. 여기에 평가하고자 하는 천상초 추출물을 처리한 후 5시간동안 배양하였다. 배양 상층액을 150㎕ 취하여 IL-1α를 정량함으로서 천상초 추출물의 염증성 사이토카인 발현억제효과를 판단하였다. IL-1α의 양은 효소면역분석법 (Enzyme-linked Immunosorbent Assay)를 이용하여 정량화하였으며, IL-1α의 생성율은 수학식 8에 의해 계산하였다.In this example, in order to evaluate the inhibitory effect of inflammatory cytokine expression expressed by UV irradiation of the extract of Cheoncheoncho obtained in Preparation Example 1, fibroblasts isolated from human epidermal tissue (Fibroblast) were placed on a 24-well test plate in a 5 × 10 4 plate. One by one and attached for 24 hours. Each well was washed once with PBS and 500 μl of PBS was added to each well. The fibroblasts were irradiated with UV 10mJ / cm 2 using an ultraviolet B (UVB) lamp (Model: F15T8, UV B 15W, Sankyo Dennki Co., Japan), after which the PBS was removed and the cell culture medium (FMEM was not added to DMEM). Medium) 350 μl was added. After treating the Cheoncheoncho extract to be evaluated here, it was incubated for 5 hours. 150 µl of the culture supernatant was taken to quantify IL-1α to determine the inflammatory cytokine expression inhibitory effect of the extract. The amount of IL-1α was quantified using Enzyme-linked Immunosorbent Assay, and the production rate of IL-1α was calculated by Equation 8.
Bo : 자외선 조사하지 않고 시료 처리하지 않은 웰의 IL-1α생성량Bo: IL-1α production in wells without UV irradiation
Bt : 자외선 조사하고 시료를 처리하지 않은 웰의 IL-1α생성량Bt: IL-1α production in wells that were not irradiated with UV light
St : 자외선 조사하고 시료를 처리한 웰의 IL-1α생성량St: IL-1α production amount of wells that were irradiated with UV light
상기 표 8의 결과에서 보는 바와 같이, 본 발명의 천상초 추출물은 자외선에 의한 염증성 사이토카인인 IL-1α의 생성을 0.013% 농도에서 60% 억제하며, 0.025%에서는 무려 73%나 억제하므로, 낮은 처리 농도에서도 자외선에 의한 염증 발생을 효과적으로 방어함을 알 수 있다.As shown in the results of Table 8, the extract of Cheoncheoncho of the present invention inhibits the production of inflammatory cytokines, IL-1α, by 60% at a concentration of 0.013%, and inhibits as much as 73% at 0.025%. It can be seen that the concentration effectively protects against inflammation caused by ultraviolet rays.
실험예Experimental Example 9. 9. 천상초Cheonsangcho 추출물을 함유하는 Containing extract 화장료의Cosmetic 피부탄력 개선효과 Skin elasticity improvement effect
본 실험예는 제조예 1에서 수득한 천상초 추출물을 함유한 화장료(실시예 1)를 제조하여 사람을 대상으로 피부탄력 개선효과를 보았으며, 천상초 추출물을 함유하지 않은 화장료(비교예 1)를 제조해 비교실험을 행하여 평가하였다. 비교실험에 사용된 화장료는 크림형태이고, 그 조성은 하기 표 9에 나타낸 바와 같다. 실험자(20세-35세의 여성) 20명을 대상으로 얼굴 오른쪽 부위에는 실시예 1의 크림을 얼굴 왼쪽 부위에는 비교예 1의 크림을 각각 1일 2회씩 연속 2개월간 도포하였다.In this Experimental Example, the cosmetics containing the extract of Cheonsangcho obtained in Preparation Example 1 (Example 1) were observed to improve skin elasticity in humans. The comparison was conducted and evaluated. The cosmetics used in the comparative experiments are in the form of a cream, the composition of which is shown in Table 9 below. For 20 experimenters (20-35 year old female), the cream of Example 1 was applied to the right side of the face and the cream of Comparative Example 1 was applied to the left side of the face twice a day for 2 consecutive months.
실험완료 후 피부탄력 개선효과는 제품 사용 전과 2개월간 사용 후에 피부탄력측정기(cutometer SEM 575, C+K Electronic Co., Germany)를 이용하여 측정하였다. 실험결과는 하기 표 10에 Cutometer SEM 575의 △R8값으로 기재하였는데 R8값은 피부의 점탄성(viscoelasticity)의 성질을 나타낸다.The skin elasticity improvement effect after the completion of the experiment was measured using a skin elasticity measuring instrument (cutometer SEM 575, C + K Electronic Co., Germany) before and after using the product for 2 months. Experimental results are described in Table 10 as ΔR8 value of Cutometer SEM 575, where R8 value represents the nature of the viscoelasticity of the skin.
상기 표에서 함량 단위는 중량%이다.The content units in the table are by weight.
상기 표 10의 결과에서 보는 바와 같이, 천상초 추출물을 함유하지 않은 크림을 도포한 비교군에 비해 천상초 추출물을 함유한 크림을 도포한 실험자의 피부 탄력개선 효과가 2배 정도 우수함을 알 수 있다.As shown in the results of Table 10, it can be seen that the skin elasticity improving effect of the experimenter applying the cream containing the cheonsangcho extract is about twice as compared to the comparison group applied the cream containing the cheonsangcho extract.
실험예 10. 천상초 추출물을 함유하는 화장료의 보습효과Experimental Example 10. Moisturizing effect of the cosmetic containing Cheonsangcho extract
상기 실험예 9에서 제조한 화장료 (실시예 1 및 비교예 1)의 보습력을 평가하기 위하여, 각 화장료가 도포된 피부를 대상으로 하여 수분 보유능을 다음과 같이 측정하였다.In order to evaluate the moisturizing power of the cosmetics prepared in Experimental Example 9 (Example 1 and Comparative Example 1), the moisture retention ability of the skin to which each cosmetic was applied was measured as follows.
22℃ 및 상대습도 45%의 항온 항습실에서 상기 실시예 및 비교예의 각 화장료를 24명의 피시험자 얼굴을 반으로 나누어 한쪽에는 실시예의 제품을 다른 한쪽에는 비교예의 제품을 도포하면서(2회/1일) 4주후의 수분 함유량을 측정하였다.In the constant temperature and humidity room of 22 ° C. and 45% RH, each of the cosmetics of Examples and Comparative Examples was divided into half of 24 test subjects while applying the product of Example to one side and the product of Comparative Example to the other (2 times / day). ) The water content after 4 weeks was measured.
측정 기기는 피부의 수분 함량에 따른 피부의 전기 용량을 측정하여 보습력을 측정하는 수분 함량 측정기 (Corneometer CM825, Courage + Khazaka사, 독일연방국)를 사용하였다. 그 결과는 하기 표 11에 나타나 있다.As a measuring device, a moisture content measuring instrument (Corneometer CM825, Courage + Khazaka, Germany) was used to measure the moisturizing power by measuring the electric capacity of the skin according to the moisture content of the skin. The results are shown in Table 11 below.
상기 표 11의 결과에서 보는 바와 같이, 본 발명의 천상초 추출물을 함유한 화장료 조성물(실시예 1)은 천상초 추출물을 함유하지 않은 화장료 조성물(비교예 1)에 비해 피부 보습효과가 월등히 뛰어났다.As shown in the results of Table 11, the cosmetic composition (Example 1) containing the cheonsangcho extract of the present invention was superior to the skin moisturizing effect compared to the cosmetic composition (Comparative Example 1) containing no cheonsangcho extract.
이상으로 본 발명의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적인 기술은 단지 바람직한 구현예일 뿐이며, 이에 본 발명의 범위가 제한되는 것이 아닌 점은 명백하다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항과 그의 등가물에 의하여 정의된다고 할 것이다.Having described the specific part of the present invention in detail, it is apparent to those skilled in the art that the specific technology is merely a preferred embodiment, and the scope of the present invention is not limited thereto. Thus, the substantial scope of the present invention will be defined by the appended claims and equivalents thereof.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020070071439A KR100816267B1 (en) | 2007-07-18 | 2007-07-18 | Cosmetic composition containing cheonsangcho extract as an active ingredient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020070071439A KR100816267B1 (en) | 2007-07-18 | 2007-07-18 | Cosmetic composition containing cheonsangcho extract as an active ingredient |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20080006503A KR20080006503A (en) | 2008-01-16 |
| KR100816267B1 true KR100816267B1 (en) | 2008-03-25 |
Family
ID=39220260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020070071439A Active KR100816267B1 (en) | 2007-07-18 | 2007-07-18 | Cosmetic composition containing cheonsangcho extract as an active ingredient |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR100816267B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101000695B1 (en) * | 2008-06-18 | 2010-12-10 | 장문식 | Cosmetic composition containing a mixed extract of natural plants having an anti-inflammatory and skin irritant effect |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9814670B2 (en) | 2014-12-04 | 2017-11-14 | Mary Kay Inc. | Cosmetic compositions |
| WO2019055961A1 (en) | 2017-09-18 | 2019-03-21 | Mary Kay Inc. | Cosmetic compositions and methods |
| KR102636105B1 (en) * | 2021-11-09 | 2024-02-14 | 경기도 | Cosmetic composition including extract of rhododendron brachycarpum or extract of rhododendron fortunei |
| CN117084960A (en) * | 2023-10-11 | 2023-11-21 | 四川省农业特色植物研究院 | A Rhododendron simsii extract, and its preparation method, composition and application |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050047075A (en) * | 2002-07-03 | 2005-05-19 | 하. 룬트벡 아크티에 셀스카브 | Spirocyclic piperidines as mch1 antagonists and uses thereof |
-
2007
- 2007-07-18 KR KR1020070071439A patent/KR100816267B1/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050047075A (en) * | 2002-07-03 | 2005-05-19 | 하. 룬트벡 아크티에 셀스카브 | Spirocyclic piperidines as mch1 antagonists and uses thereof |
Non-Patent Citations (1)
| Title |
|---|
| 한국약용작물학회지 제13권 4호, pp.199~205 (2005) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101000695B1 (en) * | 2008-06-18 | 2010-12-10 | 장문식 | Cosmetic composition containing a mixed extract of natural plants having an anti-inflammatory and skin irritant effect |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20080006503A (en) | 2008-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100954695B1 (en) | Cosmetic composition containing aspen active extract | |
| KR101176529B1 (en) | Cosmetic Composition Comprising the extract of Dendropanax morbifera as Active Ingredient | |
| KR100874114B1 (en) | Cosmetic composition containing the extract as an active ingredient | |
| KR100874115B1 (en) | Cosmetic composition containing thyme extract as an active ingredient | |
| KR20160123732A (en) | Cosmetic composition comprising the extract of cynara scolymus and brassica oleracea var. botrytis as active ingredient | |
| KR101176528B1 (en) | Cosmetic composition comprising the extract of salvia plebeia as active ingredient | |
| KR100816267B1 (en) | Cosmetic composition containing cheonsangcho extract as an active ingredient | |
| KR101817129B1 (en) | Cosmetic Composition Comprising Extracts of Pinecone of Pinus sylvestris | |
| KR101445642B1 (en) | Cosmetic composition comprising the extract of Lagerstroemia indica as active ingredient | |
| KR101176526B1 (en) | Cosmetic Composition Comprising the extract of Spiraea prunifolia var.simpliciflora as Active Ingredient | |
| KR102009204B1 (en) | Cosmetic Composition Comprising Extracts of Pinecone of Pinus sylvestris | |
| KR20090055956A (en) | Cosmetic composition for preventing skin aging and improving skin wrinkles, containing ointment extract as active ingredient | |
| KR101086227B1 (en) | Cosmetic composition containing Nado dog persimmon extract as an active ingredient | |
| KR101323068B1 (en) | Cosmetic composition comprising the extract of Viburnum odoratissimum var. awabuki as active ingredient | |
| KR100891387B1 (en) | Cosmetic composition containing hydroxy extract as an active ingredient | |
| KR101775485B1 (en) | Cosmetic composition containing fermentative extract of Spatholobus suberectus Dunn as active ingredient | |
| KR101479245B1 (en) | Cosmetic composition comprising the extract of Lagerstroemia indica as active ingredient | |
| KR101176525B1 (en) | Cosmetic Composition Comprising Acer tegmentosum Maxim as Active Ingredient | |
| KR100891083B1 (en) | Cosmetic composition containing Baekhak Youngji extract as an active ingredient | |
| KR101479244B1 (en) | Cosmetic composition comprising the extract of Lagerstroemia indica as active ingredient | |
| KR20130026678A (en) | Cosmetic composition comprising the extract of lastrea japonica as active ingredient and cosmetic method therreof | |
| KR101664878B1 (en) | Cosmetic composition containing fractions of allium hookeri as active ingredient | |
| KR101274606B1 (en) | Cosmetic composition containing the extract of jujube extracted with high pressure | |
| KR101142009B1 (en) | Cosmetic Composition Comprising Extract of Glyptostrobus pensilis as Active Ingredient | |
| KR101176522B1 (en) | Cosmetic composition comprising the extract of Cypripedium macranthum as active Ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20070718 |
|
| PA0201 | Request for examination | ||
| G15R | Request for early publication | ||
| PG1501 | Laying open of application |
Comment text: Request for Early Opening Patent event code: PG15011R01I Patent event date: 20071228 |
|
| A302 | Request for accelerated examination | ||
| PA0302 | Request for accelerated examination |
Patent event date: 20080125 Patent event code: PA03022R01D Comment text: Request for Accelerated Examination Patent event date: 20070718 Patent event code: PA03021R01I Comment text: Patent Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20080220 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20080306 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20080318 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20080318 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20100902 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20110916 Start annual number: 5 End annual number: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20130111 Year of fee payment: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20130111 Start annual number: 6 End annual number: 6 |
|
| FPAY | Annual fee payment |
Payment date: 20131127 Year of fee payment: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 20131127 Start annual number: 7 End annual number: 7 |
|
| FPAY | Annual fee payment |
Payment date: 20150112 Year of fee payment: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 20150112 Start annual number: 8 End annual number: 8 |
|
| FPAY | Annual fee payment |
Payment date: 20151211 Year of fee payment: 9 |
|
| PR1001 | Payment of annual fee |
Payment date: 20151211 Start annual number: 9 End annual number: 9 |
|
| FPAY | Annual fee payment |
Payment date: 20161227 Year of fee payment: 10 |
|
| PR1001 | Payment of annual fee |
Payment date: 20161227 Start annual number: 10 End annual number: 10 |
|
| FPAY | Annual fee payment |
Payment date: 20190109 Year of fee payment: 12 |
|
| PR1001 | Payment of annual fee |
Payment date: 20190109 Start annual number: 12 End annual number: 12 |
|
| FPAY | Annual fee payment |
Payment date: 20191226 Year of fee payment: 13 |
|
| PR1001 | Payment of annual fee |
Payment date: 20191226 Start annual number: 13 End annual number: 13 |
|
| PR1001 | Payment of annual fee |
Payment date: 20201222 Start annual number: 14 End annual number: 14 |
|
| PR1001 | Payment of annual fee |
Payment date: 20220302 Start annual number: 15 End annual number: 15 |
|
| PR1001 | Payment of annual fee |
Payment date: 20241223 Start annual number: 18 End annual number: 18 |

